Chemotherapy and bio-chemotherapy in patients with advanced melanoma: Combination therapy with a nitrosourea

Ruggero Ridolfi, L. Tanganelli, E. Scelzi, P. Manente, S. Palmeri, A. Ravaioli, L. Fiammenghi, A. Romanini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The treatment of advanced melanoma is still disappointing. In a multicenter randomized clinical trial to compare a chemotherapy (CT) with or without low doses of IL-2 and IFN (Bio-CT), the participating centers chose whether or not to add a nitrosourea, carmustine (BCNU) to the therapy. The aim of the present paper is to report the clinical results of the patients (pts) treated in both arms with BCNU. One hundred and seventy-six pts with advanced melanoma were enrolled in the study from 27 centers and a total of 18 pts also received BCNU in 3 centers. No further changes to the protocol criteria were allowed. One patient refused the treatment. No complete responses were observed. Irrespectively of the treatment arm, 9/17 pts showed a partial response to therapy (53%) (5/9 in the CT and 4/8 in the BioCT arm). The most important adverse events observed were hematological: 12 pts presented grade 3 (6 pts) or grade 4 (6 pts) leukocytopenia and 9 pts had grade 4 thrombocytopenia, all of which resolved spontaneously. The addition of a nitrosourea to CT or Bio-CT appears to improve response rates compared to the same regimens without nitrosourea. Patient tolerability is acceptable. Further studies using this combination are warranted.

Original languageEnglish
Pages (from-to)198-202
Number of pages5
JournalJournal of Chemotherapy
Volume15
Issue number2
Publication statusPublished - Apr 2003

Fingerprint

Melanoma
Drug Therapy
Carmustine
Therapeutics
Leukopenia
Interleukin-2
Randomized Controlled Trials

Keywords

  • Advanced melanoma
  • Bio-chemotherapy
  • Chemotherapy
  • Immunomodulation
  • Melanoma
  • Nitrosourea

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Ridolfi, R., Tanganelli, L., Scelzi, E., Manente, P., Palmeri, S., Ravaioli, A., ... Romanini, A. (2003). Chemotherapy and bio-chemotherapy in patients with advanced melanoma: Combination therapy with a nitrosourea. Journal of Chemotherapy, 15(2), 198-202.

Chemotherapy and bio-chemotherapy in patients with advanced melanoma : Combination therapy with a nitrosourea. / Ridolfi, Ruggero; Tanganelli, L.; Scelzi, E.; Manente, P.; Palmeri, S.; Ravaioli, A.; Fiammenghi, L.; Romanini, A.

In: Journal of Chemotherapy, Vol. 15, No. 2, 04.2003, p. 198-202.

Research output: Contribution to journalArticle

Ridolfi, R, Tanganelli, L, Scelzi, E, Manente, P, Palmeri, S, Ravaioli, A, Fiammenghi, L & Romanini, A 2003, 'Chemotherapy and bio-chemotherapy in patients with advanced melanoma: Combination therapy with a nitrosourea', Journal of Chemotherapy, vol. 15, no. 2, pp. 198-202.
Ridolfi, Ruggero ; Tanganelli, L. ; Scelzi, E. ; Manente, P. ; Palmeri, S. ; Ravaioli, A. ; Fiammenghi, L. ; Romanini, A. / Chemotherapy and bio-chemotherapy in patients with advanced melanoma : Combination therapy with a nitrosourea. In: Journal of Chemotherapy. 2003 ; Vol. 15, No. 2. pp. 198-202.
@article{e7324b1d214242bcb8e8e500869961c1,
title = "Chemotherapy and bio-chemotherapy in patients with advanced melanoma: Combination therapy with a nitrosourea",
abstract = "The treatment of advanced melanoma is still disappointing. In a multicenter randomized clinical trial to compare a chemotherapy (CT) with or without low doses of IL-2 and IFN (Bio-CT), the participating centers chose whether or not to add a nitrosourea, carmustine (BCNU) to the therapy. The aim of the present paper is to report the clinical results of the patients (pts) treated in both arms with BCNU. One hundred and seventy-six pts with advanced melanoma were enrolled in the study from 27 centers and a total of 18 pts also received BCNU in 3 centers. No further changes to the protocol criteria were allowed. One patient refused the treatment. No complete responses were observed. Irrespectively of the treatment arm, 9/17 pts showed a partial response to therapy (53{\%}) (5/9 in the CT and 4/8 in the BioCT arm). The most important adverse events observed were hematological: 12 pts presented grade 3 (6 pts) or grade 4 (6 pts) leukocytopenia and 9 pts had grade 4 thrombocytopenia, all of which resolved spontaneously. The addition of a nitrosourea to CT or Bio-CT appears to improve response rates compared to the same regimens without nitrosourea. Patient tolerability is acceptable. Further studies using this combination are warranted.",
keywords = "Advanced melanoma, Bio-chemotherapy, Chemotherapy, Immunomodulation, Melanoma, Nitrosourea",
author = "Ruggero Ridolfi and L. Tanganelli and E. Scelzi and P. Manente and S. Palmeri and A. Ravaioli and L. Fiammenghi and A. Romanini",
year = "2003",
month = "4",
language = "English",
volume = "15",
pages = "198--202",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Chemotherapy and bio-chemotherapy in patients with advanced melanoma

T2 - Combination therapy with a nitrosourea

AU - Ridolfi, Ruggero

AU - Tanganelli, L.

AU - Scelzi, E.

AU - Manente, P.

AU - Palmeri, S.

AU - Ravaioli, A.

AU - Fiammenghi, L.

AU - Romanini, A.

PY - 2003/4

Y1 - 2003/4

N2 - The treatment of advanced melanoma is still disappointing. In a multicenter randomized clinical trial to compare a chemotherapy (CT) with or without low doses of IL-2 and IFN (Bio-CT), the participating centers chose whether or not to add a nitrosourea, carmustine (BCNU) to the therapy. The aim of the present paper is to report the clinical results of the patients (pts) treated in both arms with BCNU. One hundred and seventy-six pts with advanced melanoma were enrolled in the study from 27 centers and a total of 18 pts also received BCNU in 3 centers. No further changes to the protocol criteria were allowed. One patient refused the treatment. No complete responses were observed. Irrespectively of the treatment arm, 9/17 pts showed a partial response to therapy (53%) (5/9 in the CT and 4/8 in the BioCT arm). The most important adverse events observed were hematological: 12 pts presented grade 3 (6 pts) or grade 4 (6 pts) leukocytopenia and 9 pts had grade 4 thrombocytopenia, all of which resolved spontaneously. The addition of a nitrosourea to CT or Bio-CT appears to improve response rates compared to the same regimens without nitrosourea. Patient tolerability is acceptable. Further studies using this combination are warranted.

AB - The treatment of advanced melanoma is still disappointing. In a multicenter randomized clinical trial to compare a chemotherapy (CT) with or without low doses of IL-2 and IFN (Bio-CT), the participating centers chose whether or not to add a nitrosourea, carmustine (BCNU) to the therapy. The aim of the present paper is to report the clinical results of the patients (pts) treated in both arms with BCNU. One hundred and seventy-six pts with advanced melanoma were enrolled in the study from 27 centers and a total of 18 pts also received BCNU in 3 centers. No further changes to the protocol criteria were allowed. One patient refused the treatment. No complete responses were observed. Irrespectively of the treatment arm, 9/17 pts showed a partial response to therapy (53%) (5/9 in the CT and 4/8 in the BioCT arm). The most important adverse events observed were hematological: 12 pts presented grade 3 (6 pts) or grade 4 (6 pts) leukocytopenia and 9 pts had grade 4 thrombocytopenia, all of which resolved spontaneously. The addition of a nitrosourea to CT or Bio-CT appears to improve response rates compared to the same regimens without nitrosourea. Patient tolerability is acceptable. Further studies using this combination are warranted.

KW - Advanced melanoma

KW - Bio-chemotherapy

KW - Chemotherapy

KW - Immunomodulation

KW - Melanoma

KW - Nitrosourea

UR - http://www.scopus.com/inward/record.url?scp=0038289181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038289181&partnerID=8YFLogxK

M3 - Article

C2 - 12797399

AN - SCOPUS:0038289181

VL - 15

SP - 198

EP - 202

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 2

ER -